SR90107A/ORG31540: Phase II; Phase III

In a dose-ranging Phase II study of SR90107A in 593 patients undergoing total hip replacement, SR90107A given at once daily doses of 1.5 or 3 mg reduced the risk of venous thromboembolism by 29 percen...